CAR T-cell therapies have transformed the management of several previously incurable, treatment-refractory hematologic malignancies, including Multiple Myeloma (MM). With two CAR T-cell products now approved, and additional under investigation, the therapeutic landscape continues to evolve rapidly.

In this educational podcast, Dr. Joseph Mikhael highlights key advances in CAR T-cell therapy for MM. He reviews the most impactful data published or presented in 2025 and offers expert insight into how these emerging findings may shape current and future treatment strategies.

Launch/Release Date: December 17, 2025

Activity Expiration Date: November 30, 2026

FACULTY

Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO

Professor, Clinical Genomics and Therapeutics

Translational Genomics Research Institute (TGen), City of Hope Cancer Center

Chief Medical Officer

International Myeloma Foundation

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

A number of clinical trials are underway to reduce and prevent bleeding episodes among patients with hemophilia and to improve their overall quality of life by improving joint health and addressing patient needs/concerns. These include both replacement and novel non-replacement therapies. This activity is designed to update healthcare professionals with the latest cutting-edge evidence in hemophilia treatment that was presented during the annual hematology meeting in Orlando, FL.

The Clinical Clips format will equip clinicians with the knowledge and confidence to integrate new evidence into personalized approaches, optimize patient outcomes, and improve the overall quality of care in hemophilia A and B.

Launch/Release Date: December 12, 2025 Activity Expiration Date: November 30, 2026

FACULTY

Angela Weyand, MD

Associate Professor, Pediatrics University of Michigan Medical School Pediatric Medical Director University of Michigan HTC Co-Director, Hematology and Pediatric and Adolescent Gynecology Program Ann Arbor, Michigan

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

Breakthroughs in hematologic cancers continue to emerge. Staying aligned with the newest insights from leading medical conferences is essential for healthcare providers committed to delivering cutting-edge care.

Through impactful presentations, posters and abstracts, Dr. Raajit Rampal provides expert commentary on the latest advances in Leukemia, Myelodysplastic Syndromes (MDS) and Myelofibrosis (MF) presented at the annual hematology meeting in Orlando, FL.

Launch/Release Date: December 10, 2025

Activity Expiration Date: November 30, 2026

FACULTY

Raajit Rampal, MD, PhD

Director, Myeloproliferative Neoplasms Program

Director, Center for Hematologic Malignancies

Memorial Sloan Kettering Cancer Center

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

In this podcast, Dr. Cindy Neunert, provides expert insights into emerging data on ITP pathophysiology, diagnosis, and treatment, equipping healthcare providers with the knowledge to translate new research into clinical practice and improve pediatric patient care.

Launch Date: July 7, 2025

Release Date: July 7, 2025

Expiration Date: June 30, 2026

FACULTY

Cindy Neunert, MD

Division of Pediatric Hematology

Oncology, and Stem Cell Transplantation

Columbia University Irving Medical Center

New York, New York

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

There has been unprecedented research progress in the treatment of hemophilia heralded by the development of non-replacement therapies, emerging factor mimetics, and novel gene therapy agents. In this podcast series, Dr. Jonathan C. Roberts and Dr. Mindy Simpson inform and guide on safely integrating recently approved agents into the treatment continuum while ensuring alignment with critical new breakthroughs and enabling patient-focused care pathways.

Launch Date: February 4, 2025

Release Date: February 4, 2025

Expiration Date: January 31, 2026

FACULTY

Jonathan C. Roberts, MD

Associate Medical Director

Associate Research Director

Bleeding and Clotting Disorders Institute

Associate Professor of Pediatrics and Medicine

University of Illinois College of Medicine at Peoria

Mindy Simpson, MD

Medical Director

Rush Hemophilia and Thrombophilia Center

Assistant Professor of Pediatrics in Pediatric Hematology/Oncology

Rush University Medical Center

This podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information here prior to listening to this episode.

There has been unprecedented research progress in the treatment of hemophilia heralded by the development of non-replacement therapies, emerging factor mimetics, and novel gene therapy agents. In this podcast series, Dr. Jonathan C. Roberts and Dr. Mindy Simpson inform and guide on safely integrating recently approved agents into the treatment continuum while ensuring alignment with critical new breakthroughs and enabling patient-focused care pathways.

Launch Date: February 4, 2025

Release Date: February 4, 2025

Expiration Date: January 31, 2026

FACULTY

Jonathan C. Roberts, MD

Associate Medical Director

Associate Research Director

Bleeding and Clotting Disorders Institute

Associate Professor of Pediatrics and Medicine

University of Illinois College of Medicine at Peoria

Mindy Simpson, MD

Medical Director

Rush Hemophilia and Thrombophilia Center

Assistant Professor of Pediatrics in Pediatric Hematology/Oncology

Rush University Medical Center

This podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information here prior to listening to this episode.

There has been unprecedented research progress in the treatment of hemophilia heralded by the development of non-replacement therapies, emerging factor mimetics, and novel gene therapy agents. In this podcast series, Dr. Jonathan C. Roberts and Dr. Mindy Simpson inform and guide on safely integrating recently approved agents into the treatment continuum while ensuring alignment with critical new breakthroughs and enabling patient-focused care pathways.

Launch Date: February 4, 2025

Release Date: February 4, 2025

Expiration Date: January 31, 2026

FACULTY

Jonathan C. Roberts, MD

Associate Medical Director

Associate Research Director

Bleeding and Clotting Disorders Institute

Associate Professor of Pediatrics and Medicine

University of Illinois College of Medicine at Peoria

Mindy Simpson, MD

Medical Director

Rush Hemophilia and Thrombophilia Center

Assistant Professor of Pediatrics in Pediatric Hematology/Oncology

Rush University Medical Center

This podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information here prior to listening to this episode.

There has been unprecedented research progress in the treatment of hemophilia heralded by the development of non-replacement therapies, emerging factor mimetics, and novel gene therapy agents. In this podcast series, Dr. Jonathan C. Roberts and Dr. Mindy Simpson inform and guide on safely integrating recently approved agents into the treatment continuum while ensuring alignment with critical new breakthroughs and enabling patient-focused care pathways.

Launch Date: February 4, 2025

Release Date: February 4, 2025

Expiration Date: January 31, 2026

FACULTY

Jonathan C. Roberts, MD

Associate Medical Director

Associate Research Director

Bleeding and Clotting Disorders Institute

Associate Professor of Pediatrics and Medicine

University of Illinois College of Medicine at Peoria

Mindy Simpson, MD

Medical Director

Rush Hemophilia and Thrombophilia Center

Assistant Professor of Pediatrics in Pediatric Hematology/Oncology

Rush University Medical Center

This podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information here prior to listening to this episode.

Conversations in IFN-y explores the latest advancements in understanding and managing secondary hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS), with updates from ASH 2024. Featuring discussions by leading experts, the educational activity covers breakthroughs in diagnostic technologies. Topics covered include AI-based histology models and PET/CT imaging, therapeutic innovations such as emapalumab and reduced-intensity conditioning for HSCT. The implications of these findings for improving outcomes in diverse patient populations, including malignancy- and pregnancy-associated HLH will also be discussed.

Launch Date: January 9, 2025

Release Date: January 9, 2025

Expiration Date: December 31, 2025

FACULTY

Pui Lee, MD

Assistant Professor of Pediatrics

Boston Childrens Hospital

Ashish Kumar, MD, PhD

Professor of Pediatrics

Cincinnati Children's Hospital Medical Center

Alexei Grom, MD

Professor of Pediatrics

Research Director

Division of Rheumatology

Cincinnati Children’s Hospital Medical Center

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

What’s New Doc?: CAR T-cells in Multiple Myeloma, highlights key studies and publications from 2024 on the use of these agents in earlier lines of treatment. Dr. Mikhael details how approved and emerging CAR T cell agents in multiple myeloma will impact the treatment landscape and how to better integrate these agents to enable improved outcomes among patients.

Launch Date: December 19, 2024

Release Date: December 19, 2024

Expiration Date: November 30, 2025

FACULTY

Joseph Mikhael, MD, MEd, FRCPC, FACP

Professor, Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute (TGen), City of Hope Cancer Center

Chief Medical Officer, International Myeloma Foundation

Consultant Hematologist and Director, Myeloma Research, Phase 1 Program, HonorHealth Research Institute

Adjunct Professor, College of Health Solutions, Arizona State University

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.